Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Free Cash Flow (2016 - 2025)

Traws Pharma (TRAW) has disclosed Free Cash Flow for 14 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 31.73% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached -$18.2 million, up 38.96%, while the annual FY2025 figure was -$20.8 million, 37.89% up from the prior year.
  • Free Cash Flow hit -$2.8 million in Q4 2025 for Traws Pharma, up from -$4.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.8 million in Q4 2025 and bottomed at -$11.5 million in Q3 2024.
  • Average Free Cash Flow over 5 years is -$5.1 million, with a median of -$4.4 million recorded in 2021.
  • Year-over-year, Free Cash Flow plummeted 156.79% in 2024 and then surged 65.05% in 2025.
  • Traws Pharma's Free Cash Flow stood at -$4.3 million in 2021, then increased by 8.93% to -$3.9 million in 2022, then decreased by 14.06% to -$4.4 million in 2023, then rose by 8.8% to -$4.0 million in 2024, then soared by 31.73% to -$2.8 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$2.8 million, -$4.0 million, and -$6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.